Targeting CD22 as a strategy for treating systemic autoimmune diseases

References

• BoumpasDTAustinHAVaughnEMControlled trial of pulse methylprednisolone versus 2 regimens of pulse cyclophosphamide in severe lupus nephritisLancet199234074151356175
   PubMed Web of Science ®Google Scholar
• CarnahanJSteinRQuZXEpratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximabMol Immunol20074413314116814387
   PubMed Web of Science ®Google Scholar
• CarnahanJWangPKendallREpratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro propertiesClin Cancer Res200393982S90S14506197
   PubMed Web of Science ®Google Scholar
• ChanTMLiFKTangCSOEfficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritisN Engl J Med200034311566211036121
   PubMed Web of Science ®Google Scholar
• ChaouchiNVazquezAGalanaudPB-cell antigen receptor-mediated apoptosis – importance of accessory molecules CD19 and CD22, and of surface IgM crosslLinkingJ Immunol199515430961047534787
   PubMed Web of Science ®Google Scholar
• ContrerasGLenzORothDSequential therapies for proliferative lupus nephritis – The authors replyN Engl J Med2004350251920
   Web of Science ®Google Scholar
• De VitaSZajaFSaccoSEfficacy of selective B-cell blockade in the treatment of rheumatoid arthritis – Evidence for a pathogenetic role of B-cellsArthritis Rheum20024620293312209504
   PubMed Web of Science ®Google Scholar
• DoodyGMJustementLBDelibriasCCA role in B-cell activation for CD22 and the protein-tyrosine-phosphatase ShpScience199526924247618087
   PubMed Web of Science ®Google Scholar
• DörkenBMoldenhauerGPezzuttoAHd39 (B3), A B-lineage-restricted antigen whose cell-surface expression is limited to resting and activated human lymphocytes-BJ Immunol1986136447093086431
   PubMed Web of Science ®Google Scholar
• DörnerTCrossroads of B-cell activation in autoimmunity: Rationale of targeting B-cellsJ Rheumatol200633311
   Web of Science ®Google Scholar
• DörnerTBurmesterGRThe role of B-cells in rheumatoid arthritis: mechanisms and therapeutic targetsCurr Opin Rheumatol2003152465212707577
   PubMed Web of Science ®Google Scholar
• DörnerTKaufmannJWegenerWAInitial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusArthritis Res Ther20068000000
   Web of Science ®Google Scholar
• DörnerTLipskyPESignalling pathways in B-cells: Implications for autoimmunityCurrent Concepts in Autoimmunity and Chronic Inflammation200630521340
   Google Scholar
• EdwardsJCWCambridgeGSustained improvement in rheumatoid arthritis following a protocol designed to deplete B-lymphocytesRheumatology2001402051111257159
   PubMed Web of Science ®Google Scholar
• EdwardsJCWCambridgeGB-cell targeting in rheumatoid arthritis and other autoimmune diseasesNat Rev Immunol2006639440316622478
   PubMed Web of Science ®Google Scholar
• EdwardsJCWSzczepanskiLSzechinskiJEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritisN Engl J Med200435025728115201414
   PubMed Web of Science ®Google Scholar
• EngelPNojimaYRothsteinDThe same epitope on CD22 of B-lymphocytes mediates the adhesion of erythrocytes, T-lymphocytes and BlLymphocytes, neutrophils, and monocytesJ Immunol19931504719327684411
   PubMed Web of Science ®Google Scholar
• EngelPWagnerNMillerASIdentification of the ligand-binding domains of CD22, A member of the immunoglobulin super-family that uniquely binds a sialic acid-dependent ligandJ Exp Med1995181158167535343
   PubMed Web of Science ®Google Scholar
• GoldenbergDMEpratuzumab in the therapy of oncological and immunological diseasesExp Rev Anticancer Ther20065134153
   Web of Science ®Google Scholar
• JacobiAMGoldenbergDMHiepeFDifferential effects of epratuzumab on anti-Ig-induced proliferation of peripheral blood B-cells of SLE patients and normal subjectsAnn Rheum Dis2007August 2 Epub ahead of print
   PubMedGoogle Scholar
• JacobsonDLGangeSJRoseNREpidemiology and estimated population burden of selected autoimmune diseases in the United StatesClin Immunol Immunopathol199784223439281381
   PubMedGoogle Scholar
• KelmSPelzASchauerRSialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamilyCurr Biol19944965727533044
   PubMed Web of Science ®Google Scholar
• KeystoneEB-cell targeted therapiesArthritis Res Ther20057S13S1815960817
   PubMed Web of Science ®Google Scholar
• LeandroMJEdwardsJCCambridgeGAn open study of B-lymphocyte depletion in systemic lupus erythematosusArthritis Rheum2002a462673712384926
   PubMed Web of Science ®Google Scholar
• LeandroMJEdwardsJCWCambridgeGClinical outcome in 22 patients with rheumatoid arthritis treated with B-lymphocyte depletionAnn Rheum Dis2002b61883812228157
   PubMed Web of Science ®Google Scholar
• LeonardJPColemanMKetasJCPhase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphomaJ Clin Oncol2003213051912837807
   PubMed Web of Science ®Google Scholar
• LeonardJPColemanMMatthewsJCPhase I/II trial epratuzumab (humanized anti-CD22 anti body) in non-Hodgkin’s lymphoma (NHL)Blood2002100358A
   Google Scholar
• LeungSODionASPellegriniMCEffect of Vk framework-1 glycosylation on the binding-affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation siteInt J Cancer19956053487829269
   PubMed Web of Science ®Google Scholar
• LeungSOShevitzJPellegriniMCChimerization of LL2, a rapidly internalizing antibody specific for B-cell lymphomaHybridoma199413469767737671
   PubMedGoogle Scholar
• LipskyPESystemic lupus erythematosus: an autoimmune disease of B-cell hyperactivityNat Immunol20012764611526379
   PubMed Web of Science ®Google Scholar
• MartinFChanACB-cell immunobiology in disease: evolving concepts from the clinicAnn Rev Immunol2006244679616551256
   PubMed Web of Science ®Google Scholar
• MitchisonNAWedderburnLRB-cells in autoimmunityProc Natl Acad Sci USA2000978750110922029
   PubMed Web of Science ®Google Scholar
• NitschkeLThe role of CD22 and other inhibitory co-receptors in B-cell activationCurr Opin Immunol200517290715886119
   PubMed Web of Science ®Google Scholar
• NitschkeLCarsettiROckerBCD22 is a negative regulator of B-cell receptor signallingCurr Biol19977133439016707
   PubMed Web of Science ®Google Scholar
• O’KeefeTLWilliamsGTBatistaFDDeficiency in CD22, a B-cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodiesJ Exp Med199918913071310209047
   PubMed Web of Science ®Google Scholar
• OliginoTJDalrympleSATargeting B-cells for the treatment of rheumatoid arthritisArthritis Res Ther20035S7S1115180891
   PubMed Web of Science ®Google Scholar
• OtipobyKLAnderssonKBDravesKECD22 regulates thymus-independent responses and the lifespan of B-cellsNature199638463478967951
   PubMed Web of Science ®Google Scholar
• ParkYWPryshchepSSeylerTMB-cells as a therapeutic target in autoimmune diseasesExpert Opin Ther Targets200594314515948665
   PubMed Web of Science ®Google Scholar
• Pawlak-ByczkowskaEJHansenHJDionASTwo new monoclonal-antibodies, EPB-1 and EPB-2, reactive with human lymphomaCancer Res1989494568772663143
   PubMed Web of Science ®Google Scholar
• PijpeJBootsmaHVan ImhoffGRituximab (anti-CD20) for the treatment of primary Sjogren’s syndromeArthritis Rheum200450S575
   Google Scholar
• PijpeJvan ImhoffGWSpijkervetFKLRituximab treatment in patients with primary Sjogren’s syndromeArthritis Rheum20055227405016142737
   PubMed Web of Science ®Google Scholar
• RadbruchAMuehlinghausGLugerEOCompetence and competition: the challenge of becoming a long-lived plasma cellNat Rev Immunol200667415016977339
   PubMed Web of Science ®Google Scholar
• ReffMECarnerKChambersKSDepletion of B-cells in-vivo by a chimeric mouse-human monoclonal-antibody to CD20Blood199483435457506951
   PubMed Web of Science ®Google Scholar
• SatoSMillerASInaokiMCD22 is both a positive and negative regulator of B-lymphocyte antigen receptor signal transduction: Altered signaling in CD22-deficient miceImmunity19965551628986715
   PubMed Web of Science ®Google Scholar
• ShihLBLuHHZXuanHInternalization and intracellular processing of an anti B-cell lymphoma monoclonal antibody, LL2Int J Cancer199456538458112889
   PubMed Web of Science ®Google Scholar
• StamenkovicISeedBThe B-cell antigen CD22 mediates monocyte and erythrocyte adhesionNature19903457471691828
   PubMed Web of Science ®Google Scholar
• StasiRPaganoAStipaERituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpuraBlood200198952711493438
   PubMed Web of Science ®Google Scholar
• SteinRBelisleEHansenHJEpitope specificity of the anti-(B-cell lymphoma) monoclonal antibody, LL2Cancer Immunol Immunother19933729387691407
   PubMed Web of Science ®Google Scholar
• SteinRQuZXChenSCharacterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin’s lymphomaClin Cancer Res20041028687815102696
   PubMed Web of Science ®Google Scholar
• SteinfeldSDTantLBurmesterGREpratuzumab (humanised anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II studyArthritis Res Ther20068000000
   Web of Science ®Google Scholar
• SteinfeldSDYouinouPEpratuzumab (humanised anti-CD22 antibody) in autoimmune diseasesExp Opin Biol Ther200669439
   PubMed Web of Science ®Google Scholar
• TahirHRohrerJBhatiaAHumanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximabRheumatology200544561215644390
   PubMed Web of Science ®Google Scholar
• TedderTFPoeJCHaasKMCD22: A multifunctional lectin that regulates B-lymphocyte survival and signal transductionGlycobiology2005a151197
   Web of Science ®Google Scholar
• TedderTFPoeJCHaasKMCD22: A multifunctional receptor that regulates B-lymphocyte survival and signal transductionAdv Immunol2005b8815016227086
   PubMed Web of Science ®Google Scholar
• TeelingJLFrenchRRCraggMSCharacterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasBlood2004104179380015172969
   PubMed Web of Science ®Google Scholar
• TuscanoJMRivaAToscanoSNCD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascadeBlood19999413829210438726
   PubMed Web of Science ®Google Scholar
• UchidaJJHamaguchiYOliverJAThe innate mononuclear phagocyte network depletes B-lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapyJ Exp Med200419916596915210744
   PubMed Web of Science ®Google Scholar
• ViauMZoualiMB-lymphocytes, innate immunity, and autoimmunityClin Immunol2005114172615596405
   PubMed Web of Science ®Google Scholar
• VoulgarelisMDafniUGIsenbergKAMalignant lymphoma in primary Sjogren’s syndrome – A multicenter, retrospective, clinical study by the European concerted action on Sjogren’s syndromeArthritis Rheum19994217657210446879
   PubMed Web of Science ®Google Scholar
• WilliamJEulerCPrimaroloNB-cell tolerance checkpoints that restrict pathways of antigen-driven differentiationJ Immunol200617621425116455970
   PubMed Web of Science ®Google Scholar
• WilsonGLFoxCHFauciASCDNA cloning of the B-cell membrane-protein CD22 – A mediator of B-B-cell interactionsJ Exp Med1991173137461985119
   PubMed Web of Science ®Google Scholar